This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ikeda, Y Articles by Dohi, K Search for Related Content PubMed PubMed Citation Articles by Ikeda, Y Articles by Dohi, K Social Bookmarking                         What's this?

Relationship between lupus nephritis activity and the serum level of soluble VCAM-1

T Fujimoto

M Ameno

H Shiiki

K Dohi

First Department of Internal Medicine, Nara Medical University, Nara, Japan

We measured the serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin) and soluble intercellular adhesion molecule-1 (sICAM-1) in 72 patients with systemic lupus erythematosus (SLE) (including patients with active nephritis) and 33 normal control subjects, to investigate the correlation between levels of adhesion molecules and disease and histological activity. Serum samples were obtained at the time of renal biopsy in 27 patients with lupus nephritis. The 27 patients were divided into groups according to the World Health Organization (WHO) class as follows: class I / II, n = 11; class III / IV, n = 13 and class V, n = 3. We also determined the activity index (AI) in these 27 renal biopsy specimens. We obtained serial measurements of the serum levels of soluble adhesion molecules in 11 patients to examine the difference between active and remission stages. The serum level of sVCAM-1, but not sE-selectin or sICAM-1, was correlated with parameters of SLE disease activity, including the SLE disease activity index score, the anti-double stranded DNA antibody titer, the C3 level, the C4 level and the CH50 level. The serum levels of sVCAM-1, sE-selectin and sICAM-1 were significantly higher in patients with SLE than in controls (P = 0.006, P = 0.0005 and P = 0.04, respectively). The serum level of sVCAM-1 was significantly higher in patients with active lupus nephritis (WHO classes III and IV) than in patients in inactive lupus nephritis (WHO classes I and II) (P = 0.0016). The sVCAM-1 level was significantly elevated in patients with an AI > 4 compared with patients with an AI < 4(P = 0.0025). The sVCAM-1 level decreased significantly during remission (P = 0.0033).

The serum level of sVCAM-1 was elevated in patients with active lupus nephritis (WHO classes III and IV) and in patients with high AI scores. The serum level of sVCAM-1 was correlated with the SLE disease activity and decreased during remission. Therefore, the sVCAM-1 level may be a useful marker of lupus nephritis activity.

Key Words: soluble adhesion molecule • VCAM-1 • E-selectin • ICAM-1 • lupus nephritis

Lupus, Vol. 7, No. 5, 347-354 (1998)
DOI: 10.1191/096120398678920172


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. R. Batuca, P. R. J. Ames, M. Amaral, C. Favas, D. A. Isenberg, and J. Delgado Alves Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus Rheumatology, January 1, 2009; 48(1): 26 - 31. [Abstract] [Full Text] [PDF]

				M J Lewis and D D'Cruz Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus Lupus, March 1, 2005; 14(3_suppl): s17 - s26. [Abstract] [PDF]

				M. Lewis and D. D'Cruz Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus Lupus, January 1, 2005; 14(1_suppl): s17 - s26. [Abstract] [PDF]

				C. Y. Ho, C. K. Wong, E. K. Li, L. S. Tam, and C. W. K. Lam Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus Rheumatology, January 1, 2003; 42(1): 117 - 122. [Abstract] [Full Text] [PDF]

				M.J. Cuadrado, M.A. Khamashta, and G.R.V. Hughes Migraine and stroke in young women QJM, May 1, 2000; 93(5): 317 - 318. [Full Text] [PDF]

				A. Wierzbicki Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus Lupus, March 1, 2000; 9(3): 194 - 201. [Abstract] [PDF]